[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
    "summary": "Health care stocks were lower late Tuesday afternoon, with the NYSE Health Care Index down 0.5% and",
    "url": "https://finnhub.io/api/news?id=55427c50acf73d92a339e4634b7a6e340df09a2ca208de026695145278b06c45",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768337393,
      "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
      "id": 138089298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Health care stocks were lower late Tuesday afternoon, with the NYSE Health Care Index down 0.5% and",
      "url": "https://finnhub.io/api/news?id=55427c50acf73d92a339e4634b7a6e340df09a2ca208de026695145278b06c45"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Enters Cancer Treatment Space via RemeGen Licensing Deal, UBS Says",
    "summary": "AbbVie (ABBV) is entering the PD-1/VEGF cancer treatment class, a competitive emerging area for soli",
    "url": "https://finnhub.io/api/news?id=2cc4677d4acc121d44e69494c6b5527914aef0001b9f06c1ce4243685f17bb03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768334772,
      "headline": "AbbVie Enters Cancer Treatment Space via RemeGen Licensing Deal, UBS Says",
      "id": 138091171,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) is entering the PD-1/VEGF cancer treatment class, a competitive emerging area for soli",
      "url": "https://finnhub.io/api/news?id=2cc4677d4acc121d44e69494c6b5527914aef0001b9f06c1ce4243685f17bb03"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Tuesday Afternoon",
    "summary": "Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the S",
    "url": "https://finnhub.io/api/news?id=bf2b1443ae5b48f5dbb4d87a4a9040925c4b953508fd3c01891405db23c41578",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768329695,
      "headline": "Sector Update: Health Care Stocks Decline Tuesday Afternoon",
      "id": 138087367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the S",
      "url": "https://finnhub.io/api/news?id=bf2b1443ae5b48f5dbb4d87a4a9040925c4b953508fd3c01891405db23c41578"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions",
    "summary": "AbbVie agreed to lower Medicaid prices and invest $100 billion in the US in exchange for tariff and pricing relief.",
    "url": "https://finnhub.io/api/news?id=e4ef8cd34086e88cd30402d138b3fc81c31b1f0708cc23371f7f454d9d73e900",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768327047,
      "headline": "AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions",
      "id": 138086665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie agreed to lower Medicaid prices and invest $100 billion in the US in exchange for tariff and pricing relief.",
      "url": "https://finnhub.io/api/news?id=e4ef8cd34086e88cd30402d138b3fc81c31b1f0708cc23371f7f454d9d73e900"
    }
  },
  {
    "ts": null,
    "headline": "ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon",
    "summary": "AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.",
    "url": "https://finnhub.io/api/news?id=e0f59a733f7b0042c09c23bb836a391779a36876afcc394917e5fbad77f50f3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768325700,
      "headline": "ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon",
      "id": 138087373,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.",
      "url": "https://finnhub.io/api/news?id=e0f59a733f7b0042c09c23bb836a391779a36876afcc394917e5fbad77f50f3d"
    }
  },
  {
    "ts": null,
    "headline": "Bipolar Disorder Market Opportunity Assessment and Forecast Report 2024-2034 Featuring Johnson & Johnson, Otsuka, AbbVie, Bristol Myers-Squibb, OWP, Sumitomo, Pfizer",
    "summary": "Key market opportunities in the Bipolar Disorder market include developing targeted treatments for bipolar depression due to current unmet needs, capitalizing on late-stage pipeline products projected to influence market growth, and leveraging strategic partnerships and emerging players with strong portfolios.Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The \"Bipolar Disorder: Opportunity Assessment and Forecast\" report has been added to ResearchAndMarkets.com's offering.This report covers the 7MM a",
    "url": "https://finnhub.io/api/news?id=3a3be8bfce30960c5d0a724a301e91e201d0fb9c1926dbb97f726033c338007a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768321260,
      "headline": "Bipolar Disorder Market Opportunity Assessment and Forecast Report 2024-2034 Featuring Johnson & Johnson, Otsuka, AbbVie, Bristol Myers-Squibb, OWP, Sumitomo, Pfizer",
      "id": 138086646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Key market opportunities in the Bipolar Disorder market include developing targeted treatments for bipolar depression due to current unmet needs, capitalizing on late-stage pipeline products projected to influence market growth, and leveraging strategic partnerships and emerging players with strong portfolios.Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The \"Bipolar Disorder: Opportunity Assessment and Forecast\" report has been added to ResearchAndMarkets.com's offering.This report covers the 7MM a",
      "url": "https://finnhub.io/api/news?id=3a3be8bfce30960c5d0a724a301e91e201d0fb9c1926dbb97f726033c338007a"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know",
    "summary": "AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=2c7d6026ee9cbad7c7670c7641a371d431d9666145c3a36738186fdbe8697538",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768312803,
      "headline": "Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know",
      "id": 138086667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=2c7d6026ee9cbad7c7670c7641a371d431d9666145c3a36738186fdbe8697538"
    }
  },
  {
    "ts": null,
    "headline": "Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?",
    "summary": "ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.",
    "url": "https://finnhub.io/api/news?id=deaeebebd40a90e35b35a7807231ba998ff3cd4cb2bcc9a1b6aac5bf5c585504",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768311780,
      "headline": "Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?",
      "id": 138086668,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.",
      "url": "https://finnhub.io/api/news?id=deaeebebd40a90e35b35a7807231ba998ff3cd4cb2bcc9a1b6aac5bf5c585504"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Secures Tariff Relief Pact",
    "summary": "$100 billion U.S. investment anchors agreement",
    "url": "https://finnhub.io/api/news?id=5e51f4107c4ac542dcc3a878968aa77ab9235266e71a3b822d0a81456e37b6af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768310562,
      "headline": "AbbVie Secures Tariff Relief Pact",
      "id": 138083211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "$100 billion U.S. investment anchors agreement",
      "url": "https://finnhub.io/api/news?id=5e51f4107c4ac542dcc3a878968aa77ab9235266e71a3b822d0a81456e37b6af"
    }
  },
  {
    "ts": null,
    "headline": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
    "summary": "We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]",
    "url": "https://finnhub.io/api/news?id=61ced03819d123ffc8f14f81ba7966cc2bbf9d87fe288f30c95e6fc3e0d47295",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768308508,
      "headline": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
      "id": 138083148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]",
      "url": "https://finnhub.io/api/news?id=61ced03819d123ffc8f14f81ba7966cc2bbf9d87fe288f30c95e6fc3e0d47295"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie inks MFN drug pricing deal, pledges $100bn to US R&D",
    "summary": "AbbVie is now one of 16 big pharma companies to sign MFN deals with the Trump administration and commit to the expansion of its US footprint.",
    "url": "https://finnhub.io/api/news?id=4e318746f1861a1a185f3dc95f19922016bfa927db20297a6329a54f3902ad35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768306821,
      "headline": "AbbVie inks MFN drug pricing deal, pledges $100bn to US R&D",
      "id": 138083213,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie is now one of 16 big pharma companies to sign MFN deals with the Trump administration and commit to the expansion of its US footprint.",
      "url": "https://finnhub.io/api/news?id=4e318746f1861a1a185f3dc95f19922016bfa927db20297a6329a54f3902ad35"
    }
  },
  {
    "ts": null,
    "headline": "JPM 26: Day 1 – drug prices and policy changes drive the agenda",
    "summary": "Shifting regulatory policies and evolving US drug pricing dynamics have created a favourable environment for deals.",
    "url": "https://finnhub.io/api/news?id=2cefcf663a4c2cc309b46c16ca90bb9c298c9df1d62d00affae2b4728aad36be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768301957,
      "headline": "JPM 26: Day 1 – drug prices and policy changes drive the agenda",
      "id": 138083214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Shifting regulatory policies and evolving US drug pricing dynamics have created a favourable environment for deals.",
      "url": "https://finnhub.io/api/news?id=2cefcf663a4c2cc309b46c16ca90bb9c298c9df1d62d00affae2b4728aad36be"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
    "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
    "url": "https://finnhub.io/api/news?id=e703854b3b85d22e1a0a8c62c02820a8ea079b07155cfe39db7ccb9a8b6421b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768299840,
      "headline": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
      "id": 138083151,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
      "url": "https://finnhub.io/api/news?id=e703854b3b85d22e1a0a8c62c02820a8ea079b07155cfe39db7ccb9a8b6421b7"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie reaches deal with Trump administration on drug prices in exchange for tariff relief",
    "summary": "North Chicago-based AbbVie has become the latest drugmaker to reach a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future price mandates, the company announced Monday evening. Under the voluntary agreement, AbbVie will offer “low prices” in Medicaid, a state and federally funded health insurance program for people with low incomes and ...",
    "url": "https://finnhub.io/api/news?id=afb671565f77dc7b1cc608d1623f23aee427d96ce10e99dc4e4594820977a60e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768295700,
      "headline": "AbbVie reaches deal with Trump administration on drug prices in exchange for tariff relief",
      "id": 138083216,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "North Chicago-based AbbVie has become the latest drugmaker to reach a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future price mandates, the company announced Monday evening. Under the voluntary agreement, AbbVie will offer “low prices” in Medicaid, a state and federally funded health insurance program for people with low incomes and ...",
      "url": "https://finnhub.io/api/news?id=afb671565f77dc7b1cc608d1623f23aee427d96ce10e99dc4e4594820977a60e"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie pledges $100B to US production in drug pricing deal with Trump",
    "summary": "As with the many other “most-favored-nation” deals between the white House and large pharmas, the agreement is short on details as well as its potential financial impact.",
    "url": "https://finnhub.io/api/news?id=042896caf978d384355a14eea94b0a7b832d9550b274ae6869bd510a776ceebf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768291500,
      "headline": "AbbVie pledges $100B to US production in drug pricing deal with Trump",
      "id": 138083217,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "As with the many other “most-favored-nation” deals between the white House and large pharmas, the agreement is short on details as well as its potential financial impact.",
      "url": "https://finnhub.io/api/news?id=042896caf978d384355a14eea94b0a7b832d9550b274ae6869bd510a776ceebf"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie reaches 3-year deal with White House to lower drug prices",
    "summary": "CNBC's Andrew Ross Sorkin reports on the latest news.",
    "url": "https://finnhub.io/api/news?id=bf68e31c4938e6df7cf4194454cca2b1ef957217a2a569c65a9587e7978f7416",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768288232,
      "headline": "AbbVie reaches 3-year deal with White House to lower drug prices",
      "id": 138085740,
      "image": "https://image.cnbcfm.com/api/v1/image/108251609-17683061041768306102-43474204856-1080pnbcnews.jpg?v=1768306103&w=1920&h=1080",
      "related": "ABBV",
      "source": "CNBC",
      "summary": "CNBC's Andrew Ross Sorkin reports on the latest news.",
      "url": "https://finnhub.io/api/news?id=bf68e31c4938e6df7cf4194454cca2b1ef957217a2a569c65a9587e7978f7416"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie granted tariff exemption via deal with Trump administration",
    "summary": "AbbVie granted tariff exemption via deal with Trump administration",
    "url": "https://finnhub.io/api/news?id=6d481c6233474b74c70c8ebbf052b9bb2bce89c139581a9067f34727935529b1",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768264834,
      "headline": "AbbVie granted tariff exemption via deal with Trump administration",
      "id": 138079584,
      "image": "",
      "related": "ABBV",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6d481c6233474b74c70c8ebbf052b9bb2bce89c139581a9067f34727935529b1"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices",
    "summary": "As part of the three-year deal, the Trump administration exempted AbbVie from tariffs and future pricing mandates, the company said.",
    "url": "https://finnhub.io/api/news?id=69c6e5c0947481ee87f5c26f6374af1f835f9cf529988bf241420b190a047c2b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768262580,
      "headline": "AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices",
      "id": 138083218,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "As part of the three-year deal, the Trump administration exempted AbbVie from tariffs and future pricing mandates, the company said.",
      "url": "https://finnhub.io/api/news?id=69c6e5c0947481ee87f5c26f6374af1f835f9cf529988bf241420b190a047c2b"
    }
  }
]